Zobrazeno 1 - 10
of 139
pro vyhledávání: '"Danielle J Vugts"'
Autor:
Hasan Alsaid, Tinamarie Skedzielewski, Mary V Rambo, Kristen Hunsinger, Bao Hoang, William Fieles, Edward R Long, James Tunstead, Danielle J Vugts, Matthew Cleveland, Neil Clarke, Christopher Matheny, Beat M Jucker
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176075 (2017)
The purpose of this work was to use various molecular imaging techniques to non-invasively assess GSK2849330 (anti HER3 ADCC and CDC enhanced 'AccretaMab' monoclonal antibody) pharmacokinetics and pharmacodynamics in human xenograft tumor-bearing mic
Externí odkaz:
https://doaj.org/article/8a2ccc9895534f1ca10fbfa2c7a01728
Autor:
Yvonne W S Jauw, Josée M Zijlstra, Daphne de Jong, Danielle J Vugts, Sonja Zweegman, Otto S Hoekstra, Guus A M S van Dongen, Marc C Huisman
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0169828 (2017)
Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging bioma
Externí odkaz:
https://doaj.org/article/aa08a95257eb45329d6e3009ae7b3c4c
Autor:
Pieter J Gaillard, Chantal C M Appeldoorn, Rick Dorland, Joan van Kregten, Francesca Manca, Danielle J Vugts, Bert Windhorst, Guus A M S van Dongen, Helga E de Vries, David Maussang, Olaf van Tellingen
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e82331 (2014)
Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that tightly regulates the diffusion of endogenous molecules but also xe
Externí odkaz:
https://doaj.org/article/f54ba57af8444eeda07da4624d406acf
Autor:
Antonia A. Högnäsbacka, Alex J. Poot, Christophe Plisson, Jonas Bergare, David R. Bonsall, Stuart P. McCluskey, Lisa A. Wells, Esther Kooijman, Robert C. Schuit, Mariska Verlaan, Wissam Beaino, Guus A. M. S. van Dongen, Danielle J. Vugts, Charles S. Elmore, Jan Passchier, Albert D. Windhorst
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Background Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in non-small cell lung cancer. Conventional tyrosine kinase inhibitors target the mutation site in the ATP binding pocket, thereby inhibiting the re
Externí odkaz:
https://doaj.org/article/625cc69bf6ed4690bf32bf9fa866699c
Autor:
Magdalena Mileva, Elisabeth G. E. de Vries, Thomas Guiot, Zéna Wimana, Anne-Leen Deleu, Carolien P. Schröder, Yolene Lefebvre, Marianne Paesmans, Sigrid Stroobants, Manon Huizing, Philippe Aftimos, Jolien Tol, Winette T. A. Van der Graaf, Wim J. G. Oyen, Danielle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Adrienne H. Brouwers, Martine Piccart-Gebhart, Patrick Flamen, Géraldine Gebhart
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HER2
Externí odkaz:
https://doaj.org/article/b8159ecb1674471b9a212c77843626e6
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-31 (2023)
Abstract Background Positron emission tomography (PET) is a powerful, non-invasive preclinical and clinical nuclear imaging technique used in disease diagnosis and therapy assessment. Fluorine-18 is the predominant radionuclide used for PET tracer sy
Externí odkaz:
https://doaj.org/article/c441d1b7df3c4c29ab3acf5ac9bf233c
Autor:
Kevin S. Thorneloe, Armin Sepp, Sean Zhang, Laura Galinanes-Garcia, Paul Galette, Wasfi Al-Azzam, Danielle J. Vugts, Guus van Dongen, Phillip Elsinga, Johan Wiegers, Andor W. J. M. Glaudemans, Veena Vincent, Jessica Renaux, Matt Szapacs, Mary Birchler, Matthew Cleveland, Mats Bergstrom, Marie Davies
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Conjugation or fusion to AlbudAbs™ (albumin-binding domain antibodies) is a novel approach to extend the half-life and alter the tissue distribution of biological and small molecule therapeutics. To understand extravasation kinetics and ex
Externí odkaz:
https://doaj.org/article/eba10547950944e2b456a3b51b283abc
Autor:
Esther Hulleman, Gertjan J.L. Kaspers, Guus A.M.S. van Dongen, Pieter Wesseling, W. Peter Vandertop, David P. Noske, Angel M. Carcaboso, Naomi Petersen, Susanna J.E. Veringa, Viola Caretti, Carla F.M. Molthoff, Dannis G. van Vuurden, Danielle J. Vugts, A. Charlotte P. Sewing, Tonny Lagerweij, Marc H.A. Jansen
A heatmap generated using K-means clustering of expression of VEGF-A associated genes; LG-BSG samples (blue) in the disease type histology (upper legends) cluster with normal brain (purple). DIPG (red) clusters with GBM (green). DIPG (green), pHGG/GB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cdb51e427760771bbe087f83ba0b370
https://doi.org/10.1158/1535-7163.22504251
https://doi.org/10.1158/1535-7163.22504251
Autor:
Esther Hulleman, Gertjan J.L. Kaspers, Guus A.M.S. van Dongen, Pieter Wesseling, W. Peter Vandertop, David P. Noske, Angel M. Carcaboso, Naomi Petersen, Susanna J.E. Veringa, Viola Caretti, Carla F.M. Molthoff, Dannis G. van Vuurden, Danielle J. Vugts, A. Charlotte P. Sewing, Tonny Lagerweij, Marc H.A. Jansen
Supplemental Figure 2: VEGF mRNA expression in DIPG in comparison to normal brain (n=31) as analyzed by R2 (R2.amc.nl), clustered by stage of disease; unknown (n=10), pretreatment (n=2) and postmortem (n=23)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3200bf734a936950db47118d68b97ac
https://doi.org/10.1158/1535-7163.22504245.v1
https://doi.org/10.1158/1535-7163.22504245.v1
Autor:
Joyce F. Liu, Alison Hannah, Virginia Paton, Susan K. Lyman, Olga Vasiljeva, Ivan A. Zein, Tam Dang, Song Wang, C. Willemien Menke van der Houven van Oordt, Guus A.M.S. van Dongen, Gerben J.C. Zwezerijnen, Marc C. Huisman, Danielle J. Vugts, Iris H.C. Miedema, Stella K. Kim, James J. Harding, Shadia Jalal, Javier Garcia-Corbacho, Misako Nagasaka, Patricia LoRusso, Randy F. Sweis, Rachel E. Sanborn, Nataliya Uboha, Funda Meric-Bernstam, Alexander Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Valentina Boni
Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20af64024eca128b7e651ebd8e6392cb
https://doi.org/10.1158/1078-0432.22486622
https://doi.org/10.1158/1078-0432.22486622